ACADIA Pharmaceuticals

Robbins LLP Is Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of ACADIA Pharmaceuticals, Inc. (NASDAQGS: ACAD) breached their fiduciary duties to shareholders. ACADIA is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address neurological and related central nervous system disorders.

ACADIA Postpones Its New Drug Application

On March 11, 2015, ACADIA issued a press release announcing that it would delay submitting a New Drug Application for the treatment of Parkinson’s disease psychosis, NUPLAZID, until the second half of 2015. The company chose to delay the application to allow for additional time to ensure that ACADIA could support the production and distribution of the treatment, if it were to be approved by regulators. In a separate announcement, ACADIA announced the immediate retirement of its Chief Executive Officer, Uli Hacksell. On this news, shares of ACADIA dropped over 22%, or $10.16, in after-hours trading closing March 11, 2015 at $44.76 per share, and opening March 12, 2015 at $34.60 per shares.

In light of this news, Robbins LLP’s investigation focuses on whether ACADIA’s board of directors breached its fiduciary duties to shareholders.

ACADIA Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.

Skip to content